On June 23, 2025, Dr. Reddy’s Laboratories Limited, a global pharmaceutical company headquartered in Hyderabad, Telangana, India, announced the allotment of 10,685 equity shares under its Employee Stock Options Schemes. The move reflects the company’s continued commitment to rewarding and retaining top talent.
Dr. Reddy’s Laboratories Limited, a leading Indian multinational pharmaceutical company based in Hyderabad, Telangana, has announced the allotment of 10,685 equity shares on June 23, 2025. The allotment was made to eligible employees who exercised their stock options under the company’s Employee Stock Options Scheme, 2002 and the ADR Stock Options Scheme, 2007.
According to an official communication from the company, the equity shares carry a face value of Re. 1/- each and rank pari passu with existing shares of the company. The shares were issued at various exercise prices, including 4,265 shares at Re. 1/-, 5,800 shares at ₹735.80, and 620 shares at ₹1,060.20. Following this allotment, the total issued and paid-up equity capital of the company stands at ₹83.45 crore comprising 83,45,81,775 equity shares.
The shares are listed on BSE Limited, National Stock Exchange of India, New York Stock Exchange (NYSE), and NSE IFSC Limited. This strategic allotment not only strengthens employee ownership but also reinforces Dr. Reddy’s commitment to long-term value creation through employee participation.
Dr. Reddy’s, incorporated in 1984, operates in major global markets including the US, Europe, and emerging economies. The company is known for its work in pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs).
The communication was signed by Mr. K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy’s Laboratories Limited.